Prana Completes Phase 2 Huntington Disease Trial With PBT2
July 23, 2013 at 09:10 AM EDT
Prana Biotechnology (NASDAQ: PRAN ) today announced the successful completion of Reach2HD, a phase 2 clinical trial in patients with early to mid-stage Huntington disease. The Company expects to announce the results arising from the trial in October. Reach2HD is a randomised, double-blind, placebo-controlled Phase 2 trial testing the
